Melagatran is a reversible, selective, orally active direct inhibitor of thrombin with a Ki of 2 nM. It directly binds to the active site of thrombin, inhibiting the thrombin-mediated conversion of fibrinogen to fibrin. Melagatran reduces the DNA binding activity of NF-κB and AP-1, and has shown to reduce fibrin deposition in organs, alleviate ischemic brain damage, and reduce the size of advanced atherosclerotic lesions.
- Reversible, selective thrombin inhibitor
- Inhibits thrombin-mediated fibrinogen to fibrin conversion
- Reduces DNA binding activity of NF-κB and AP-1
- Alleviates ischemic brain damage
- Decreases advanced atherosclerotic lesion size
- Used in cardiovascular disease research
- Investigated for neurological disease studies